Abstract
The development of new or direct oral anticoagulants was triggered by the disadvantages of classic oral anticoagulation, which was isolated in Link’s laboratory in 1940. Some of these limitations are the individual variation in response to these drugs, drug interaction and the need for regular laboratory monitoring. With increasing comorbidity and life expectancy in populations these limitations led to interruption of treatment or even underuse of treatment in light of potential side effects. With the introduction of novel oral anticoagulants some of these drawbacks are targeted whereas even these drugs also have some limitations and should be given with cautions and not to all patients having an indication for anticoagulation.
Keywords: Coumadin, novel oral anticoagulation, thrombembolism, warfarin.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Rationale for Development of New Oral Anticoagulants
Volume: 15 Issue: 2
Author(s): Muharrem Akin, Julian Widder, Ibrahim Akin, Michael Brehm and Andreas Schäfer
Affiliation:
Keywords: Coumadin, novel oral anticoagulation, thrombembolism, warfarin.
Abstract: The development of new or direct oral anticoagulants was triggered by the disadvantages of classic oral anticoagulation, which was isolated in Link’s laboratory in 1940. Some of these limitations are the individual variation in response to these drugs, drug interaction and the need for regular laboratory monitoring. With increasing comorbidity and life expectancy in populations these limitations led to interruption of treatment or even underuse of treatment in light of potential side effects. With the introduction of novel oral anticoagulants some of these drawbacks are targeted whereas even these drugs also have some limitations and should be given with cautions and not to all patients having an indication for anticoagulation.
Export Options
About this article
Cite this article as:
Akin Muharrem, Widder Julian, Akin Ibrahim, Brehm Michael and Schäfer Andreas, Rationale for Development of New Oral Anticoagulants, Cardiovascular & Hematological Disorders-Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871529X1502151209110044
DOI https://dx.doi.org/10.2174/1871529X1502151209110044 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Cardiovascular Diagnostic Testing: Use and Limits of Biochemical Markers (Executive Editors: Aurelio Leone and Stefano Taddei)]
Current Pharmaceutical Design Investigational Positive Inotropic Agents for Acute Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Subject index to volume 1
Current HIV Research Gastroprotective Role of Glucocorticoids During NSAID-induced Gastropathy
Current Pharmaceutical Design Renal Function Impairment in Patients Undergoing Elective EVAR vs. Elective Open Repair During Follow up Period: A Systematic Review of the Literature
Current Vascular Pharmacology Terminalia arjuna in Cardiovascular Diseases: Making the Transition from Traditional to Modern Medicine in India
Current Pharmaceutical Biotechnology Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Diagnosis of Cardiovascular Diseases Using Retinal Images Through Vessel Segmentation Graph
Current Medical Imaging Progress Towards Discovery of Antifibrotic Drugs Targeting Synthesis of Type I Collagen
Current Medicinal Chemistry Heart Score Estimation by Specialized Nurses in a Greek Urban Population
Current Vascular Pharmacology Cerebral Aneurysm Formation in Nitric Oxide Synthase-3 Knockout Mice
Current Neurovascular Research Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design Zwitterionic Imidazolium Salt: An Efficient Organocatalyst for the One-Pot Synthesis of 5,6-Unsubstituted 1,4-Dihydropyridine Scaffolds
Current Organocatalysis Dermatological, Cardiovascular and Neurological Morphohistopathological Effects of Fluoropyrimidine-based Chemotherapy in Humans
Clinical Cancer Drugs Vascular Risk Factors and Neurodegeneration in Ageing Related Dementias: Alzheimer’s Disease and Vascular Dementia
Current Alzheimer Research Novel Biomarkers Assessing the Calcium Deposition in Coronary Artery Disease
Current Medicinal Chemistry Insulin Resistance as a Therapeutic Target for Improved Endothelial Function:Metformin
Current Drug Targets - Cardiovascular & Hematological Disorders Central-To-Peripheral Arterial Stiffness Gradient in Hemodialyzed Patients Depends on the Location of the Upper-limb Vascular Access
Current Hypertension Reviews Radiological Diagnosis of Renal Thrombosis in Children
Current Pediatric Reviews Statins and Solid Organ Transplantation
Current Pharmaceutical Design